Skip to main content
SpringerLink
Log in

Modulation of mediator release from human intestinal mast cells by sulfasalazine and 5-aminosalicylic acid

  • Original Articles
  • Published:
Digestive Diseases and Sciences Aims and scope Submit manuscript

Abstract

Intestinal mast cells are thought to contribute to the mucosal inflammation in ulcerative colitis and Crohn's disease through release of inflammatory mediators. Since sulfasalazine and its metabolite 5-aminosalicylic acid are effective therapeutic agents in inflammatory bowel disease and have been shown to inhibit generation of inflammatory products in other cells, we examined the effect of these agentsin vitro on human intestinal mast cell mediator release. Sulfasalazine (5×10−4−10 −3 M) was found to significantly enhance goat anti-human IgE-induced histamine release from intestinal mast cells, which is the same response as seen in human blood basophils, whereas its metabolite 5-aminosalicylic acid was an effective inhibitor of stimulated histamine release in both mast cells and basophils. 5-Aminosalicylic acid also inhibited production of prostaglandin D2 by the stimulated intestinal mast cells. Sulfasalazine alone, without immunologic stimulation, did not induce histamine release from mast cells or basophils, but the enhancement of ongoing mast cell activation by sulfasalazine may explain some cases of adverse reactions to the drug. The inhibition of mast cell histamine release and prostaglandin generation by 5-aminosalicylic acid demonstrates a potential therapeutic modality of this agent.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Dvorak AM, Monohan RA, Osage JE, Dickersin GR: Mast cell degranulation in Crohn's disease. Lancet 1:498, 1978

    Google Scholar 

  2. Sommers SC: Mast cells and paneth cells in ulcerative colitis. Gastroenterology 51:841–848, 1966

    Google Scholar 

  3. Ranlöv P, Nielsen MH, Wanstrup J: Ultrastructure of the ileum in Crohn's disease: Immune lesion and mastocytosis. Scand J Gastroenterol 7:471–476, 1972

    Google Scholar 

  4. Dvorak AM, Monohan RA, Osage JE, Dickersin GR: Transmission electron microscopic studies. II. Immunologic inflammatory response. Alterations of mast cells, basophils, eosinophils and the microvasculature. Hum Pathol 11:606–619, 1980

    Google Scholar 

  5. Wasserman SI: Mediators of immediate hypersensitivity. J Allergy Clin Immunol 72:101–115, 1983

    Google Scholar 

  6. Peters SP, MacGlashan DW Jr, Schulman ES, Schleimer RP, Hayes EC, Rokach J, Adkinson NF Jr, Lichtenstein LM: Arachidonic acid metabolism in purified human lung mast cells. J Immunol 132:1972–1979, 1984

    Google Scholar 

  7. Plaut M, Pierce J, Watson C, Hanley-Hyde J, Nordan R, Paul WE: Stimulated mast cell lines secrete interleukins. FASEB J 3:6101, 1989

    Google Scholar 

  8. Singleton JW, Law DH, Kelley ML, Mekhjian HS, Sturdevant RAL: National Cooperative Crohn's Disease Study: Adverse reactions to study drugs. Gastroenterology 77:870–882, 1979

    Google Scholar 

  9. van Hees PAM, Bakker JH, Van Tongeren JHM: Effect of sulphapyridine, 5-aminosalicylic acid, and placebo in patients with idiopathic proctitis. A study to determine the active therapeutic moiety of sulphasalazine. Gut 21:632–635, 1980

    Google Scholar 

  10. Rasmussen SN, Binder V, Maier K, Bondesen S, Fischer C, Klotz U, Hansen SH, Hvidberg EF: Treatment of Crohn's disease with per oral 5-aminosalicylic acid. Gastroenterology 85:1350–1353, 1983

    Google Scholar 

  11. Stenson WF, Lobos EA: Inhibition of platelet thromboxane synthetase by sulfasalazine. Biochem Pharmacol 32:2205–2209, 1983

    Google Scholar 

  12. Stenson WF, Lobos E: Sulfasalazine inhibits the synthesis of chemotactic lipids by neutrophils. J Clin Invest 69:494–497, 1982

    Google Scholar 

  13. Boughton-Smith NK, Hawkey CJ, Whittle BJR: Sulphasalazine and the inhibition of thromboxane synthesis in human colonic mucosa. Br J Pharmacol 80:604P, 1983

    Google Scholar 

  14. Peskar BM, Dreyling KW, Peskar BA, May B, Goebell H: Enhanced formation of sulfidopeptide-leukotrienes in ulcerative colitis and Crohn's disease: Inhibition by sulfasalazine and 5-aminosalicylic acid. Agents Actions 18:381–383, 1986

    Google Scholar 

  15. Fox CC, Dvorak AM, Peters SP, Kagey-Sobotka A, Lichtenstein LM: Isolation and characterization of human intestinal mucosal mast cells. J Immunol 135:483–491, 1985

    Google Scholar 

  16. Barrett KE, Tashof TL, Metcalfe DD: Inhibition of IgE-mediated mast cell degranulation by sulfasalazine. Eur J Pharmacol 107:279–281, 1985

    Google Scholar 

  17. Gilbert HS, Ornstein L: Basophil counting with a new staining method using alcian blue. Blood 46:279–286, 1975

    Google Scholar 

  18. Lichtenstein LM, Osler AG: Studies on the mechanisms of hypersensitivity phenomena. Histamine release from human leukocytes by ragweed pollen antigen. J Exp Med 120:507–530, 1964

    Google Scholar 

  19. Siraganian RP: An automated continuous flow system for the extraction and fluorometric analysis of histamine. Anal Biochem 57:383–394, 1974

    Google Scholar 

  20. Schulman ES, Newball HH, Demers LM, Fitzpatrick FA, Adkinson NF Jr: Anaphylactic release of thromboxane A2, prostaglandin D2, and prostacyclin from human lung parenchyma. Am Rev Respir Dis 124:402–406, 1981

    Google Scholar 

  21. Taffet SL, Das KM: Sulfasalazine adverse effects and desensitization. Dig Dis Sci 28:833–842, 1983

    Google Scholar 

  22. Das KM, Eastwood MA, McManus JPA, Sircus W: The metabolism of salicylazosulphapyridine in ulcerative colitis. Gut 14:631–641, 1973

    Google Scholar 

  23. Peppercorn MA, Goldman P: Distribution studies of salicylazosulfapyridine and its metabolites. Gastroenterology 64:240–245, 1973

    Google Scholar 

  24. Tung RS, Lichtenstein LM: Cyclic AMP agonist inhibition increases at low levels of histamine release from human basophils. J Pharmacol Exp Ther 218:642–646, 1981

    Google Scholar 

  25. Adams GK III, Lichtenstein LM:In vitro studies of antigeninduced bronchospasm: Effect of antihistamine and SRS-A antagonist on response of sensitized guinea pig and human airways to antigen. J Immunol 122:555–562, 1979

    Google Scholar 

  26. Fox CC, Lazenby A, Moore WC, Yardley JH, Bayless TM, Lichtenstein LM: Enhancement of human intestinal mast cell mediator release in active ulcerative colitis. Gastroenterology 99:119–124, 1990

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Johns Hopkins Asthma and Allergy Center, The Johns Hopkins University School of Medicine, 21224, Baltimore, Maryland

    Charity C. Fox MD, Wendy C. Moore BS & Lawrence M. Lichtenstein MD

Authors
  1. Charity C. Fox MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Wendy C. Moore BS
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Lawrence M. Lichtenstein MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Additional information

This work was supported by the National Foundation for Ileitis and Colitis and the National Institute of Allergy and Infectious Disease grants AI07290 and AI08270.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Fox, C.C., Moore, W.C. & Lichtenstein, L.M. Modulation of mediator release from human intestinal mast cells by sulfasalazine and 5-aminosalicylic acid. Digest Dis Sci 36, 179–184 (1991). https://doi.org/10.1007/BF01300753

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF01300753

Key Words

Search

Navigation